Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
09 mars 2022 17h30 HE
|
Immunocore Holdings Limited
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq:...
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
03 mars 2022 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...
Immunocore to present at the SVB Leerink Global Healthcare Conference
11 févr. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq:...
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
06 déc. 2021 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable...
Immunocore to present at the Jefferies London Healthcare Conference
11 nov. 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq:...
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
10 nov. 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions...
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
08 sept. 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
04 juin 2021 09h05 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
Immunocore to present at upcoming investor conferences
27 mai 2021 16h30 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...
Immunocore Reports First Quarter 2021 Financial Results
12 mai 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...